OptimizeRx (OPRX) Debt to Equity (2019 - 2025)
OptimizeRx (OPRX) has disclosed Debt to Equity for 5 consecutive years, with $0.2 as the latest value for Q4 2025.
- Quarterly Debt to Equity fell 28.65% to $0.2 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.2 through Dec 2025, down 28.65% year-over-year, with the annual reading at $0.2 for FY2025, 28.65% down from the prior year.
- Debt to Equity hit $0.2 in Q4 2025 for OptimizeRx, down from $0.23 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.31 in Q3 2024 to a low of $0.2 in Q4 2025.
- Historically, Debt to Equity has averaged $0.27 across 3 years, with a median of $0.28 in 2024.
- Biggest five-year swings in Debt to Equity: dropped 2.03% in 2024 and later fell 28.65% in 2025.
- Year by year, Debt to Equity stood at $0.29 in 2023, then fell by 2.03% to $0.28 in 2024, then dropped by 28.65% to $0.2 in 2025.
- Business Quant data shows Debt to Equity for OPRX at $0.2 in Q4 2025, $0.23 in Q3 2025, and $0.24 in Q2 2025.